

# Stian Knappskog

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4384331/publications.pdf>

Version: 2024-02-01

97  
papers

14,623  
citations

147566

31  
h-index

46693

89  
g-index

105  
all docs

105  
docs citations

105  
times ranked

28749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
2	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	13.7	1,760
3	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015, 21, 751-759.	15.2	711
4	Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017, 32, 169-184.e7.	7.7	534
5	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251-1343.	6.0	348
6	Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track – Letter. <i>Cancer Research</i> , 2010, 70, 6393-6396.	0.4	278
7	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. <i>Nature Genetics</i> , 2014, 46, 487-491.	9.4	254
8	Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. <i>Clinical Cancer Research</i> , 2010, 16, 3356-3367.	3.2	235
9	Clinical effect of temozolomide–based chemotherapy in poorly differentiated endocrine carcinoma after progression on first–line chemotherapy. <i>Cancer</i> , 2011, 117, 4617-4622.	2.0	233
10	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	13.7	229
11	The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. <i>Cancer Cell</i> , 2011, 19, 273-282.	7.7	104
12	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	2.4	85
13	The level of synthesis and secretion of <i>Gussia princeps</i> luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. <i>Journal of Biotechnology</i> , 2007, 128, 705-715.	1.9	84
14	Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	2.3	79
15	EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. <i>Neuro-Oncology</i> , 2016, 18, 1644-1655.	0.6	78
16	CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e3062.	1.1	74
17	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	2.4	69
18	Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. <i>PLoS ONE</i> , 2011, 6, e19249.	1.1	65

#	ARTICLE	IF	CITATIONS
19	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225.	1.5	64
20	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2022, 29, 1-14.	1.6	62
21	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958.	3.2	58
22	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R47.	2.2	58
23	P53 and its molecular basis to chemoresistance in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S23-S30.	1.5	57
24	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer &amp; Metabolism</i> , 2019, 7, 6.	2.4	51
25	SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. <i>European Journal of Cancer</i> , 2012, 48, 1988-1996.	1.3	43
26	APOBEC3A/B deletion polymorphism and cancer risk. <i>Carcinogenesis</i> , 2018, 39, 118-124.	1.3	39
27	MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. <i>Oncotarget</i> , 2011, 2, 251-258.	0.8	39
28	Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. <i>Tumor Biology</i> , 2015, 36, 1003-1013.	0.8	37
29	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326.	2.0	37
30	Effects of the <i>MDM2</i> promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. <i>Transcription</i> , 2011, 2, 207-210.	1.7	34
31	Outcome after surgery for primary hyperaldosteronism may depend on <i>KCNJ5</i> tumor mutation status: a population-based study from Western Norway. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 869-874.	0.8	34
32	MDM4 SNP34091 (rs4245739) and its effect on breast, colon, lung, and prostate cancer risk. <i>Cancer Medicine</i> , 2015, 4, 1901-1907.	1.3	33
33	Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4235.	1.8	32
34	Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. <i>Molecular Cancer</i> , 2010, 9, 173.	7.9	29
35	Influence of <i>MDM2</i> SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. <i>International Journal of Cancer</i> , 2015, 137, 96-103.	2.3	27
36	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Concomitant inactivation of the p53 and pRB functional pathways predicts resistance to DNA damaging drugs in breast cancer <i>in vivo</i> . <i>Molecular Oncology</i> , 2015, 9, 1553-1564.	2.1	23
38	A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1155-1163.	1.5	22
39	Constitutional Mosaic Epimutations – a hidden cause of cancer?. <i>Cell Stress</i> , 2019, 3, 118-135.	1.4	22
40	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014, 5, 8223-8234.	0.8	22
41	Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. <i>Oncotarget</i> , 2016, 7, 28637-28646.	0.8	22
42	The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian but not endometrial cancer. <i>Tumor Biology</i> , 2016, 37, 10697-10702.	0.8	20
43	Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines. <i>Cell Death Discovery</i> , 2017, 3, 17026.	2.0	20
44	CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia. <i>Oncotarget</i> , 2013, 4, 1438-1448.	0.8	20
45	Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. <i>Scientific Reports</i> , 2019, 9, 5244.	1.6	19
46	Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 11.	1.1	18
47	Mutations and polymorphisms of the p21B transcript in breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 908-910.	2.3	16
48	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 867-876.	1.7	16
49	Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue. <i>PLoS ONE</i> , 2013, 8, e74618.	1.1	16
50	High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 177-190.	1.1	16
51	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241.	0.8	16
52	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. <i>Nature Communications</i> , 2022, 13, 69.	5.8	16
53	The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6000-6004.	3.2	15
54	Effect of CYP19 rs6493497 and rs7176005 haplotype status on <i>in vivo</i> aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 128, 69-75.	1.2	15

#	ARTICLE	IF	CITATIONS
55	High expression of the p53 isoform $\hat{1}^3$ is associated with reduced progression-free survival in uterine serous carcinoma. <i>BMC Cancer</i> , 2018, 18, 684.	1.1	15
56	<i>TP53</i> status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. <i>Acta Oncologica</i> , 2014, 53, 1347-1355.	0.8	14
57	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. <i>BMC Cancer</i> , 2017, 17, 97.	1.1	14
58	Alterations of the retinoblastoma gene in metastatic breast cancer. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 319-326.	1.7	13
59	Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. <i>European Journal of Endocrinology</i> , 2012, 166, 941-949.	1.9	13
60	MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. <i>PLoS ONE</i> , 2012, 7, e36263.	1.1	12
61	Tumor cells interact with red blood cells via galectin-4 - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 401-409.	2.1	11
62	Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. <i>BMC Cell Biology</i> , 2017, 18, 17.	3.0	11
63	Assessment of tumor suppressor promoter methylation in healthy individuals. <i>Clinical Epigenetics</i> , 2020, 12, 131.	1.8	11
64	DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	11
65	Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2514-2516.	0.3	10
66	Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. <i>BMC Cancer</i> , 2012, 12, 454.	1.1	9
67	Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2790-2797.	1.1	8
68	Effects of SNP variants in the $17\hat{1}^2$ -HSD2 and $17\hat{1}^2$ -HSD7 genes and $17\hat{1}^2$ -HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 192-198.	1.2	8
69	Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0134351.	1.1	8
70	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. <i>Scientific Reports</i> , 2016, 6, 33153.	1.6	8
71	Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 2163-2174.	0.4	8
72	Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. <i>Gene</i> , 2021, 793, 145747.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Prevalence of the CHEK2 R95* germline mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 19.	0.6	6
74	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 228-235.	1.2	6
75	Introducing nano-scale quantitative polymerase chain reaction. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 923-926.	1.0	5
76	BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?. <i>Clinical Epigenetics</i> , 2018, 10, 128.	1.8	5
77	Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 23463.	1.6	5
78	Chemosensitivity and p53; new tricks by an old dog. <i>Breast Cancer Research</i> , 2012, 14, 325.	2.2	4
79	Impact of <i>MDM2</i> promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. <i>Biomarkers</i> , 2021, 26, 302-308.	0.9	4
80	MDM2 SNP309 and risk of cervical cancer. <i>Tumor Biology</i> , 2014, 35, 6185-6186.	0.8	3
81	Promoter SNPs rs116896264 and rs73933062 form a distinct haplotype and are associated with galectin-4 overexpression in colorectal cancer. <i>Mutagenesis</i> , 2016, 31, 401-408.	1.0	3
82	The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2- $\Delta$ 5 in Breast Cancer Cells. <i>Translational Oncology</i> , 2017, 10, 806-817.	1.7	3
83	The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer. <i>PLoS ONE</i> , 2020, 15, e0225357.	1.1	3
84	Letter to the editor MDM2 SNP309 and risk of endometrial cancer. <i>Polish Journal of Pathology</i> , 2013, 1, 69-69.	0.1	2
85	<i>ramr</i> : an R/Bioconductor package for detection of rare aberrantly methylated regions. <i>Bioinformatics</i> , 2021, 38, 133-140.	1.8	2
86	NEW DOCTORIAL CANCER RESEARCH:Germline Genetic Alterations Affecting CDKN2A, MDM2, and CDKN1A in Melanoma and Breast Cancer Patients. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 261-263.	0.2	1
87	P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 2749-2749.	2.3	1
88	Genomic heterogeneity in primary breast cancer: Clinical implications.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11004-11004.	0.8	1
89	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 555-555.	0.8	1
90	Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10509-10509.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Re: <i>Murine double minute 2</i> promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. <i>International Journal of Urology</i> , 2012, 19, 966-966.	0.5	0
92	MDM2 SNP309 and risk of endometrial cancer. <i>Tumor Biology</i> , 2014, 35, 7285-7286.	0.8	0
93	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18.	0.4	0
94	Title is missing!. , 2020, 15, e0225357.		0
95	Title is missing!. , 2020, 15, e0225357.		0
96	Title is missing!. , 2020, 15, e0225357.		0
97	Title is missing!. , 2020, 15, e0225357.		0